China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of ...

If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try ...

Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo ...

For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be on the horizon ...

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a ...

Eight months after more than doubling down on its construction of a $2 billion drug manufacturing facility in Holly Springs, ...

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray ...

B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and ...

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off ...

Boehringer Ingelheim has continued its rise up patient groups’ ranking of rare disease companies, adding to last year’s gains to cement its status toward the top of the leaderboards. | Boehringer ...

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no ...

After receiving a checkered regulatory scorecard in 2024, Aurobindo’s sterile injectables and oncology unit is back in the ...